Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Acquisitions (2021 - 2022)

10x Genomics' Acquisitions history spans 2 years, with the latest figure at $2.5 million for Q4 2022.

  • For Q4 2022, Acquisitions changed N/A year-over-year to $2.5 million; the TTM value through Dec 2023 reached $4.0 million, changed 0.0%, while the annual FY2022 figure was $4.0 million, 26.62% down from the prior year.
  • Acquisitions for Q4 2022 was $2.5 million at 10x Genomics, up from $1.5 million in the prior quarter.
  • Across five years, Acquisitions topped out at $5.5 million in Q1 2021 and bottomed at $1.5 million in Q3 2022.